ACAD vs GSK
ACADIA Pharmaceuticals Inc. vs GSK plc — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
GSK
GSK plc
64
Insufficient Data
| Metric | ACAD | GSK |
|---|
| AI Score |
69
|
64
|
| Price |
$29.41
|
$50.91
|
| P/E Ratio |
13.07×
|
15.80×
|
| ROE |
31.9%
|
35.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
73.3%
|
| Debt / Equity |
0.06×
|
1.03×
|
| Dividend Yield |
0.0%
|
3.5%
|
| RSI (14) |
78.4
|
39.2
|
| Beta |
0.845
|
0.3
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus GSK.
ACAD leads by 5 points.
ACAD scores 69/100 (Buy) versus GSK at 64/100 (Insufficient Data).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical